These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 22104047)

  • 1. Pyoderma gangrenosum associated with inflammatory bowel disease. Report of two cases with good response to infliximab.
    Carrasco Cubero C; Ruiz Tudela MM; Salaberri Maestrojuan JJ; Pérez Venegas JJ
    Reumatol Clin; 2012; 8(2):90-2. PubMed ID: 22104047
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Favorable response to infliximab treatment in a patient with active Crohn disease and pyoderma gangrenosum.
    Triantafillidis JK; Cheracakis P; Sklavaina M; Apostolopoulou K
    Scand J Gastroenterol; 2002 Jul; 37(7):863-5. PubMed ID: 12190104
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Infliximab for treatment of pyoderma gangrenosum associated with inflammatory bowel disease.
    Regueiro M; Valentine J; Plevy S; Fleisher MR; Lichtenstein GR
    Am J Gastroenterol; 2003 Aug; 98(8):1821-6. PubMed ID: 12907338
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Use of infliximab in pyoderma gangrenosum.
    Hewitt D; Tait C
    Australas J Dermatol; 2007 May; 48(2):95-8. PubMed ID: 17535196
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anti-tumor necrosis factor alpha monoclonal antibody (infliximab) for the treatment of Pyoderma gangrenosum associated with Crohn's disease.
    Zaccagna A; Bertone A; Puiatti P; Picciotto F; Sprujevnik T; Santucci R; Rossini FP
    Eur J Dermatol; 2003; 13(3):258-60. PubMed ID: 12804985
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Improvement of Pyoderma gangrenosum and psoriasis associated with Crohn disease with anti-tumor necrosis factor alpha monoclonal antibody.
    Tan MH; Gordon M; Lebwohl O; George J; Lebwohl MG
    Arch Dermatol; 2001 Jul; 137(7):930-3. PubMed ID: 11453813
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [The role of biologic therapy in the treatment of extraintestinal manifestations and complications of inflammatory bowel disease].
    Kujundzić M
    Acta Med Croatica; 2013 Apr; 67(2):195-201. PubMed ID: 24471303
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Infliximab for treatment of pyoderma gangrenosum associated with clinically inactive Crohn's disease. A case report.
    Kouklakis G; Moschos J; Leontiadis GI; Kadis S; Mpoumponaris A; Molyvas E; Minopoulos GI
    Rom J Gastroenterol; 2005 Dec; 14(4):401-3. PubMed ID: 16400359
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pyoderma gangrenosum associated with crohn disease: effect of TNF-alpha blockade with infliximab.
    Ljung T; Staun M; Grove O; Fausa O; Vatn MH; Hellström PM
    Scand J Gastroenterol; 2002 Sep; 37(9):1108-10. PubMed ID: 12374238
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Infliximab for peristomal pyoderma gangrenosum.
    Mimouni D; Anhalt GJ; Kouba DJ; Nousari HC
    Br J Dermatol; 2003 Apr; 148(4):813-6. PubMed ID: 12752145
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Predictive factors for erythema nodosum and pyoderma gangrenosum in inflammatory bowel disease.
    Ampuero J; Rojas-Feria M; Castro-Fernández M; Cano C; Romero-Gómez M
    J Gastroenterol Hepatol; 2014 Feb; 29(2):291-5. PubMed ID: 23927379
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Improvement of idiopathic pyoderma gangrenosum during treatment with anti-tumor necrosis factor alfa monoclonal antibody.
    Dini V; Romanelli M; Bertone M; Talarico S; Bombardieri S; Barachini P
    Int J Low Extrem Wounds; 2007 Jun; 6(2):108-13. PubMed ID: 17558009
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pustular pyoderma gangrenosum.
    Leger M; Newlove T; Chu J; Meehan S; Stein J
    Dermatol Online J; 2011 Oct; 17(10):17. PubMed ID: 22031643
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Infliximab for the treatment of disseminated pyoderma gangrenosum associated with ulcerative colitis. Case report and literature review.
    Juillerat P; Christen-Zäch S; Troillet FX; Gallot-Lavallée S; Pannizzon RG; Michetti P
    Dermatology; 2007; 215(3):245-51. PubMed ID: 17823524
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Use of infliximab in a patient with pyoderma gangrenosum and rheumatoid arthritis.
    Tada M; Nakanishi T; Hirata C; Okano T; Sugioka Y; Wakitani S; Nakamura H; Koike T
    Mod Rheumatol; 2010 Dec; 20(6):598-601. PubMed ID: 20680379
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pyoderma gangrenosum as initial manifestation of Graves' disease.
    Livideanu C; Lipsker D; Paul C; Juillard J; Schubert B
    Clin Exp Dermatol; 2006 Sep; 31(5):659-61. PubMed ID: 16780496
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A case of pyoderma gangrenosum with ulcerative colitis treated with combined approach: infliximab and surgery.
    Andrisani G; Guidi L; Papa A; Potenza AE; Cervelli D; Armuzzi A
    J Crohns Colitis; 2013 Jun; 7(5):421-6. PubMed ID: 22889645
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pyoderma gangrenosum outside the context of inflammatory bowel disease treated successfully with infliximab.
    Swale VJ; Saha M; Kapur N; Hoffbrand AV; Rustin MH
    Clin Exp Dermatol; 2005 Mar; 30(2):134-6. PubMed ID: 15725238
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Successful treatment with infliximab of refractory pyoderma gangrenosum in 2 patients with inflammatory bowel diseases.
    Cocco A; Angelucci E; Viscido A; Caprilli R
    Inflamm Bowel Dis; 2007 Oct; 13(10):1317-9. PubMed ID: 17508417
    [No Abstract]   [Full Text] [Related]  

  • 20. [Pyoderma gangrenosum, a nonintestinal manifestation of Lesniowski-Crohn's disease in a 15 years old girl].
    Müller L; Bala G; Kuczyńska R; Czerwionka-Szaflarska M
    Med Wieku Rozwoj; 2006; 10(2):463-73. PubMed ID: 16825717
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.